Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Operating Income of -$472.13 million for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$472.13M | -10.9% |
| 2024 | -$425.74M | -8.7% |
| 2023 | -$391.49M | -0.6% |
| 2022 | -$389.05M | -2.8% |
| 2021 | -$378.42M | -12.7% |
| 2020 | -$335.92M | -6.2% |
| 2019 | -$316.27M | +12.7% |
| 2018 | -$362.48M | -13.0% |
| 2017 | -$320.79M | -59.6% |
| 2016 | -$200.99M | -69.3% |
| 2015 | -$118.70M | -119.3% |
| 2014 | -$54.13M | -39.2% |
| 2013 | -$38.88M | -69.1% |
| 2012 | -$23.00M | -38.3% |
| 2011 | -$16.63M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$116.87M | -13.7% | +8.0% |
| June 30, 2025 | -$127.06M | -20.1% | -19.2% |
| March 31, 2025 | -$106.63M | -15.8% | -3.7% |
| September 30, 2024 | -$102.81M | -1.9% | +2.8% |
| June 30, 2024 | -$105.82M | -12.9% | -14.9% |
| March 31, 2024 | -$92.07M | -1.6% | +8.7% |
| September 30, 2023 | -$100.90M | -10.8% | -7.7% |
| June 30, 2023 | -$93.70M | +4.0% | -3.4% |
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -10.9% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, AGIOS PHARMACEUTICALS, INC.’s operating income has declined by 2738.9% (from -$16.63 million to -$472.13 million).
- The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: